|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of the eight possible three-locus CTLA-4 haplotypes (+49A/G, -318C/T, and CT60A/G) identified, multivariate regression analysis confirmed the positive association of ACG (odds ratio [OR], 1.93; 95% confidence interval [CI], 1.26 to 2.94), GCG (OR, 2.40; 95% CI, 1.11 to 5.21), and GTA (OR, 4.67; 95% CI, 1.52 to 14.39) haplotypes with T1D, after confounding variables were adjusted for.
|
20610662 |
2010 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Optimal regulation of blood glucose level in Type I diabetes using insulin and glucagon.
|
30893335 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present article describes the effect on glucose of small doses of subcutaneous glucagon to revert hypoglycemia and prevent severe events in small children with type 1 diabetes using a continuous glucose monitoring.
|
31673895 |
2020 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1/hIgG2 was found to be effective in reducing the incidence of diabetes in multiple-low-dose streptozotocin-induced type 1 diabetes in mice.
|
20856794 |
2010 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of these, 56 patients had insulin deficiency (fasting and glucagon-stimulated plasma C-peptide concentrations < or = 0.2 nmol/l and < or = 0.32 nmol/l, respectively), and they were subdivided into typical (n = 26) and atypical Type I (insulin-dependent) diabetes mellitus (n = 30) according to clinical manifestation.
|
11793020 |
2001 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was undertaken to examine whether 3 to 4 weeks of therapy with pramlintide or liraglutide might help to blunt postprandial hyperglycemia in T1D by suppressing plasma glucagon responses to mixed-meal feedings.
|
29211871 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study compared the ability of glucagon to restore plasma glucose (PG) after mild hypoglycemia in patients with type 1 diabetes on an isocaloric high-carbohydrate diet (HCD) versus a low-carbohydrate diet (LCD).
|
27797928 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Delays in blood glucose determination, insulin delivery and its absorption remain challenges in the rapidly evolving closed loop continuous subcutaneous insulin and glucagon delivery systems developed for children with type 1 diabetes.
|
29072820 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.
|
29504662 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changes in gastric emptying and GLP-1 secretion and reduced glucose absorption through glucose-lipid competition may contribute to lower glycemia after a high-glycemic index meal with EVOO in T1D patients.
|
30567626 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 and ghrelin responses to the test meal, as well as the prevalence of GI symptoms, were similar between patients with T1DM and controls and between patients with T1DM with normal GE and those with delayed GE.
|
29659867 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Less than 10% (T1D: 10.9%; T2D: 3.5%) filled a glucagon prescription after the ED visit.
|
30035620 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that when glucagon activity is blocked in the setting of type 1 diabetes, the plasma ghrelin level rises, preventing hypoglycemia.
|
28487437 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinediones as add-on therapies to insulin in T1D.
|
29991320 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The VPP can be used to evaluate automated insulin and glucagon delivery algorithms, so-called artificial pancreas (AP) algorithms that are currently being used to help people with T1D better manage their glucose levels.
|
31344037 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted a four-session, randomized crossover trial involving 15 adults with type 1 diabetes treated with continuous subcutaneous insulin infusion who exercised fasting in the morning at ∼55% VO<sub>2max</sub> for 45 min under conditions of no intervention (control), 50% basal insulin reduction, 40-g oral glucose tablets, or 150-μg subcutaneous glucagon (MDG).
|
29776987 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice with congenital loss of the glucagon receptor gene (Gcgr<sup>-/-</sup> mice) remain normoglycemic in insulinopenic conditions, suggesting that unopposed glucagon action is the driving force for hyperglycemia in Type-1 Diabetes Mellitus (T1DM).
|
30170980 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The area under the curve for serum glucagon levels after arginine infusion in FT1DM patients was significantly smaller than that in T1DM, T2DM, or SPIDDM patients but was similar to that in PDM patients.
|
30203124 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most insulin<sup>low</sup> cells contained abundant glucagon and other α-cell markers, suggesting that α-cells drive much of the insulin<sup>low</sup> phenotype in T1D.
|
30552110 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to determine the impact of C-peptide status on glucagon response and endogenous glucose production (EGP) during hypoglycemia in patients with T1DM.
|
29408994 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The nucleotide substitutions in exon 4 in the patient with type 1 diabetes and that with fibrocalculous pancreatopathy occurred at codons 103 and 84 while that in exon 5 in the patient with type 1 diabetes occurred at codon 141, changing the codons from CAT to CAC, GTG to GCG, and ACT to AAT and resulting in H103H silent, V84A and T141N missense mutations, respectively.
|
11796176 |
2002 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
A validated glucose-insulin-glucagon model was used to describe seven virtual patients with insulin pump-treated type 1 diabetes.
|
28922582 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
A closed-loop system for automatic insulin and glucagon delivery, also referred to as an artificial pancreas, has the potential to reduce the self-management burden of type 1 diabetes and reduce the risk of hypo- and hyperglycemia.
|
28929796 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As expected, hypoinsulinemia in T1D was associated with hyperglycemia, low levels of glucagon, hyperlipidemia, significant body fat loss, and increased white adipose tissue expression of Fgf21, a marker for lipolysis.
|
31242337 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abnormal glucagon secretion and functional alterations of the exocrine pancreas have been described in patients with type 1 diabetes (T1D), but their respective anatomical substrata have seldom been investigated.
|
29352311 |
2018 |